# A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin

> **NCT01054118** · PHASE1 · COMPLETED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 18 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** JNJ-38431055
- **DRUG:** Sitagliptin 100 mg
- **DRUG:** JNJ-38431055 + Sitagliptin 100 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01054118
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12
- **Primary completion:** —
- **Final completion:** 2010-02
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01054118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01054118, "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Doses of JNJ-38431055, Sitagliptin, and Co-administration of JNJ-38431055 and Sitagliptin". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01054118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*